Attendees visit the 23andMe booth at the RootsTech annual genealogical event in Salt Lake City in 2019. (George Frey/Reuters) By Daniel Gilbert and Elizabeth Dwoskin

The fate of genetic data belonging to millions of 23andMe customers is again up in the air, as the bankrupt company seeks a judge’s permission to consider another bid from its co-founder and undisclosed financial backers after previously accepting an offer from Regeneron Pharmaceuticals.

A nonprofit research institute backed by Anne Wojcicki, 23andMe’s co-founder and former CEO, has been pressing 23andMe to consider additional bids purportedly topping Regeneron’s $256 million cash offer last month, arguing that the bankruptcy auction was closed prematurely. That has put 23andMe in a bind, with the firm saying in court f

See Full Page